STOCK TITAN
  1. Home
  2. News
  3. TLIS

Talis Biomedical Corporation - $TLIS STOCK NEWS

Welcome to our dedicated page for Talis Biomedical Corporation news (Ticker: $TLIS), a resource for investors and traders seeking the latest updates and insights on Talis Biomedical Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Talis Biomedical Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Talis Biomedical Corporation's position in the market.

News
Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
Rhea-AI Summary
Talis Biomedical Corporation (Nasdaq: TLIS) has initiated a process to explore strategic alternatives to maximize shareholder value amidst progress in developing the Talis One® system and current market conditions. The company has appointed a special committee to consider various strategic alternatives, engaged TD Cowen as a financial advisor, and Seyfarth Shaw as a legal advisor. Talis Biomedical is reducing its workforce by approximately 90 percent, consolidating operations to a single site in Chicago, and implementing additional cost-saving measures to lower cash burn. Third Quarter 2023 Financial Results show a decrease in revenue and operating expenses, with a net loss of $15.7 million. Cash and cash equivalents as of September 30, 2023, were $88.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.48%
Tags
none
-
News
Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
earnings
-
News
Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
conferences earnings
News
Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
none
-
News
New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
none
-
News
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Talis Biomedical regains compliance with Nasdaq's minimum bid price requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags
none
News
Talis Biomedical Announces 1-for-15 Reverse Stock Split
Rhea-AI Summary
Talis Biomedical Corporation (Nasdaq: TLIS) has announced a 1-for-15 reverse stock split of its common stock. The split is intended to increase the per share market price and regain compliance with Nasdaq's minimum bid price requirement. The company's common stock will trade on Nasdaq under the symbol 'TLIS' with a new CUSIP number. The reverse stock split will combine 15 shares into one new share, resulting in approximately 1.8 million issued and outstanding shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
none
-
News
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
management
-
News
Talis Biomedical Announces Business Update and First Quarter 2023 Financial Results
Rhea-AI Summary
Talis Biomedical announces business update and financial results for Q1 2023. They have established the ability to manufacture cartridges and instruments at scale. They have prioritized the development of four test panels for women's and sexual health. They have received feedback from the FDA on pre-submissions for respiratory and CT/NG/TV test panels. They have improved net cash used in operating activities by 62% year-over-year. Revenue for Q1 2023 was $1.2 million, compared to $3.2 million in Q1 2022. Operating expenses decreased from $36.2 million to $20.2 million. Net loss for Q1 2023 was $17.8 million. Unrestricted cash and cash equivalents as of March 31, 2023, were $113.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.46%
Tags
earnings
News
Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023
Rhea-AI Summary
Talis Biomedical Corporation will provide a business update and financial results on May 11, 2023, after market close. The live webcast of the event can be accessed through the investor section of Talis Biomedical's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
earnings
Stock TLIS logo
Talis Biomedical Corporation

Nasdaq:TLIS

TLIS Rankings

#5231 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

TLIS Stock Data

16.94M
1.01M
8.31%
43.93%
0.73%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About TLIS

high complexity diagnostics at the point-of-need. bridging the gap between discovery and delivery at slipchip we integrate high-complexity laboratory assays, into an easy to perform, affordable and accessible sample-to-answer format across a wide range of environments. what if physicians could make rapid, individualized optimal treatment decisions? today, patients are often forced to endure days of waiting for lab results. as a result, doctors initially treat everyone with a strong cocktail of drugs. this approach is costly and can be harmful to patients.it also leads to serious drug resistance problems. our technology will allow doctors to provide optimal therapies to patients sooner. empowering physicians to make informed treatment decisions quickly. minimizing risks and reducing patient recovery times.